Home » Biophytis to Conduct Phase 2/3 Trial of Investigational Sarconeos for COVID-19
Biophytis to Conduct Phase 2/3 Trial of Investigational Sarconeos for COVID-19
Biophytis is set to conduct a phase 2/3 trial in the U.S. of its investigational drug Sarconeos for acute respiratory failure associated with COVID-19.
The initial trial will assess the treatment’s safety and efficacy in 50 hospitalized COVID-19 patients. The second phase will evaluate the efficacy of the drug in 300 additional patients.
Biophytis is developing Sarconeos for the treatment of sarcopenia, a skeletal muscle disorder, and Duchenne muscular dystrophy.
Upcoming Events
-
07May
-
14May
-
30May